Eligible health centers purchased $81.4 billion in discounted drugs under the federal 340B program in 2024, an increase of 23% from the previous year as

An FDA staff analysis of the safety of pediatric Covid-19 shots has been finalized and sent to the agency’s vaccine and biologics head Vinay Prasad.

Health insurers are facing two colliding forces heading into 2026: Medical costs are challenging the way they do business, and major technology shifts are finally

Roche and BioNTech stole the show at this year’s San Antonio Breast Cancer Symposium. The Swiss drugmaker unveiled Phase 3 data for its oral SERD

Another TIGIT program has failed in the clinic, this time in a Phase 3 study. Arcus and Gilead said on Friday that their anti-TIGIT antibody